Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1833-1838

  Zhong, Da Ni ^a   Ning, Qiu Yue ^a   Wu, Ji Zhou ^a   Zang, Ning ^a   Wu, Jian Lin ^a   Hu, Die Fei ^a   Luo, Shuang Yan ^b   Huang, Ai Chun ^a   Li, Lan Lan ^a   Li, Guo Jian ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E;

ARTICLE; CONTROLLED STUDY; FAMILIAL INCIDENCE; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SAMPLE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; LIVER NEOPLASMS; MALE; PEDIGREE; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSCRIPTOME;

EID: 84867233433     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02368.x     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-8.
3. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (Suppl 4): 5-13.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
5. Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011; 81 (Suppl 1): 41-9.
6. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 223-43, vii-x.
7. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
8. Zhang CY, Huang TR, Yu JH et al. Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer 2010; 29: 545-50.
9. Yu MW, Chang HC, Chen PJ et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002; 31: 1008-15.
10. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
11. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 252-7.
12. Khoury MJ, Beaty TH, Liang KY. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 1988; 127: 674-83.
13. Gong HM. [Family aggregation of hepatocarcinoma-preliminary analysis.] Zhonghua Zhong Liu Za Zhi 1985; 7: 408-10. (In Chinese.).
14. Yu MW, Chang HC, Liaw YF et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92: 1159-64.
15. Hassan MM, Spitz MR, Thomas MB et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 2009; 50: 334-41.
16. Gao Y, Jiang Q, Zhou X et al. HBV infection and familial aggregation of liver cancer: an analysis of case-control family study. Cancer Causes Control 2004; 15: 845-50.
17. Qiao B, Wang J, Xie J et al. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med 2012; 29: 832-40.
18. Wu FX, Wang Q, Zhang ZM et al. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. Cancer Lett 2009; 279: 163-70.
19. Qiu JG, Fan J, Liu YK et al. Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 299-305.
20. Pan J, Sun LC, Tao YF et al. ATP synthase ecto-alpha-subunit: a novel therapeutic target for breast cancer. J Transl Med 2011; 9: 211.
21. Gatlin-Bunai CL, Cazares LH, Cooke WE et al. Optimization of MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100 kDa mass range. J Proteome Res 2007; 6: 4517-24.
22. Callesen AK, Christensen R, Madsen JS et al. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 291-300.
23. Tirumalai RS, Chan KC, Prieto DA et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096-103.
24. Tai DI, Changchien CS, Hung CS, Chen CJ. Replication of hepatitis B virus in first-degree relatives of patients with hepatocellular carcinoma. Am J Trop Med Hyg 1999; 61: 716-9.
25. Zinkin NT, Grall F, Bhaskar K et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14: 470-7.
26. Junrong T, Huancheng Z, Feng H et al. Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma. J Biosci 2011; 36: 659-68.
27. Pleguezuelo M, Lopez-Sanchez LM, Rodriguez-Ariza A et al. Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. World J Hepatol 2010; 2: 127-35.
28. Jiang ZH, Zhang ZY, He M et al. [The screening and identification of Apolipoprotein A-II from serum differential proteins in hepatocellular carcinoma patients.] Zhonghua Gan Zang Bing Za Zhi 2010; 18: 445-9. (In Chinese.).
29. Blanc JF, Lalanne C, Plomion C et al. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 2005; 5: 3778-89.
30. Yokoyama Y, Kuramitsu Y, Takashima M et al. Protein level of apolipoprotein E increased in human hepatocellular carcinoma. Int J Oncol 2006; 28: 625-31.
31. Lichtor T. Gene expression of apolipoprotein E in human brain tumors. Neurosci Lett 1992; 138: 287-90.
32. Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000; 60: 6281-7.
33. Zhang HL, Wu J, Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol 2010; 2010: doi: 10.1155/2010/186813.
34. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011; 53: 467-74.
35. He QY, Zhu R, Lei T et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J Cell Biochem 2008; 103: 740-52.
36. Sung HJ, Ahn JM, Yoon YH et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011; 10: 1383-95.
37. Vermaat JS, Gerritse FL, van der Veldt AA et al. Validation of Serum Amyloid alpha as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol 2012; doi: 10.1016/j.eururo.2012.01.020.
38. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S et al. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem 2010; 58: 1015-23.
39. Li J, Xie Z, Shi L et al. Purification, identification and profiling of serum amyloid A proteins from sera of advanced-stage cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 890: 3-9.